Enolen

Enolen is a novel, localized drug delivery implant developed for the treatment of localized prostate cancer. It is designed to deliver enzalutamide, an anti-androgen drug, directly into the prostate tissue. This targeted approach aims to minimize systemic side effects commonly associated with oral or systemic anti-androgen therapy by concentrating the therapeutic effect at the tumor site while sparing other tissues from unnecessary exposure. The Enolen implant represents an innovative strategy for improving quality of life in men with prostate cancer by potentially avoiding surgery or radiation therapy and reducing adverse effects related to testosterone suppression throughout the body. The technology is being developed and clinically tested by Alessa Therapeutics[1][6].

Brand names

Enolen

Other names

enzalutamide implantenzalutamide-eluting implant